Navigation Links
China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates

HAIKOU CITY, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the first quarter ended March 31, 2009.

    First Quarter 2009 Financial Highlights

    -- Revenue increased 10.9% to $13.0 million from $11.7 million in the
       first quarter of 2008
    -- Gross profit increased to $5.9 million from $5.8 million in the first
       quarter of 2008
    -- Gross margin was 45.6% from 49.6% in the first quarter of 2008
    -- EPS was $0.09, compared to $0.11 in the first quarter of 2008

    First Quarter 2009 Business Updates

    -- Appointed Mr. Frank Waung to Chief Financial Officer, and nominated Ms.
       Heung Mei Tsui to the Board of Directors.
    -- Initiated clinical trials for the generic version of the leading
       hypertension drug Candesartan.
    -- Received the SFDA's approval to produce Tiopronin Enteric-Coated
       Capsules, which is listed in the National Medical Insurance Program,
       thus allowing patients to obtain reimbursement.
    -- Dried powder production line expansion completed and production

Revenues for the first quarter of 2009 increased approximately 10.9% to $13.0 million, from $11.7 million in the first quarter of 2008. The increase in revenues was due to an increase in sales of existing products as well as sales from recently-launched products. Revenue performance was offset by uncertainty related to China's healthcare reform plan, as bulk buyers delayed purchase orders in anticipation of lower pricing and subsidies from the new insurance catalogue and essential drug list, which are not yet published.

Gross profit for the first quarter of 2009 grew to $5.9 million from $5.8 million in the first quarter of 2008. Gross margin was 45.6%, compared to 49.6% during the first quarter of 2008. Gross margin performance reflects increased sales of lower margin products.

Operating expenses for the first quarter of 2009 increased 61.7% to $1.9 million compared to $1.2 million in the same period of 2008. Selling expenses contributed to the greatest increase for the period, increasing 78.4% to $602,760 from $337,792 in the first quarter of 2008, which is due to the Company's substantial expanding investment in distribution channels and overall marketing efforts. Allowance for bad debt was $774,932 compared to $472,975 the same period in 2008. The 63.8% increase was due to the majority of products were sold to state-owned hospitals, whose payments are slow, but reliable. General and administrative expenses were $488,047 in the first quarter of 2009, up from $342,818 in the first quarter of 2008. This increase reflects higher operating expenses that occurred as a result of expanded business operations.

Operating income for the first quarter of 2009 totaled $4.1 million, compared to $4.7 million for the same period in 2008.

Net income for the first quarter of 2009 was $3.7 million, compared to $4.2 million reported in the same period of 2008. Diluted earnings per share were $0.09 in the first quarter of 2009, compared to $0.11 in the first quarter of 2008. The EPS calculation is based on 42.3 million fully-diluted shares, increased from 37.3 million shares in the prior year period.

China Pharma's President and CEO, Ms. Zhilin Li, stated, "We are pleased to report a quarter with continued growth during the global economic crisis. Our increased sales of new and existing products contributed to stable growth in the first quarter. We are confident that the recent decline in purchase orders from bulk buyers will reverse, and our revenue growth will return to the higher levels enjoyed previously. Combined with our increased marketing efforts and distribution capabilities, we anticipate improved margins and profitability in 2009."

Balance Sheet

As of March 31, 2009, the Company had cash and cash equivalents of $5.2 million, which represented 6.4% of total assets; compared to $0.7 million in the same period for 2008, which represented 1.4% of the total assets. Compared to the position of December 31, 2008, this was a decrease of $1.8 million. This was primarily due to the investing activities in new drug development in the first quarter of 2009.

    Business Update

    -- On April 30, 2009, the Board of Directors appointed Mr. Frank Waung to
       Chief Financial Officer, and nominated Ms. Heung Mei Tsui to join the

    -- On February 11, 2009, the Company announced the initiation of clinical
       trials for the generic version of the leading hypertension drug

    -- On January 12, 2009, the Company announced that China's State Food and
       Drug Administration ("SFDA") approved the production of Tiopronin
       Enteric-Coated Capsules. Tiopronin is listed in the National Medical
       Insurance Program, thus allowing patients to obtain reimbursement.

    -- The expansion of our dried powder production line is complete and
       production has commenced. The new capacity will allow us to meet growth
       in demand for dried powder formulation products over the next few

Financial Guidance

While healthcare reform will likely cause changes to the competitive landscape of pharmaceutical market in China, we expect 20% top line growth in 2009 based on our existing product portfolio and new products, as well as our efforts to drive market share and expand our distribution network.

Ms. Li concluded, "In the first quarter of 2009, we saw great potential from our newly-launched products and strong demand for our existing products. Our increased marketing efforts and distribution expansion will boost future growth in the rest of 2009. We continue to expect China's healthcare reform to bring real and significant change to the Chinese pharmaceutical industry. China Pharma is well-positioned to quickly adjust its marketing and product strategy according to the new regulatory environment when it becomes certain, and to drive shareholder value."

Conference Call

The Company will hold a conference call at 8:00 am ET on May 15, 2009 to discuss fiscal first quarter 2009 results. Listeners may access the call by dialing 1-800-901-5241or 1-617-786-2963 for international callers, access code: 38020856. A webcast will also be available through CPHI's website at . A replay of the call will be available through May 22, 2009. Listeners may access the replay by dialing 1-888-286- 8010 or 1-617-801-6888 for international callers, access code: 72616938.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by a scalable GMP-certified manufacturing infrastructure. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit .

Safe Harbor Statement

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

                         CHINA PHARMA HOLDINGS, INC.
                           AND COMPREHENSIVE INCOME

                                         For the Three Months ended March 31,
                                                    2009              2008

    Revenue                                    $12,991,982       $11,717,045
    Cost of revenue                              7,063,227         5,909,768

    Gross profit                                 5,928,755         5,807,277

    Operating expenses:
    Selling expenses                               602,760           337,792
    General and administrative expenses            488,047           342,818
    Bad debt expense                               774,932           472,975
    Total operating expenses                     1,865,739         1,153,585

    Income from operations                       4,063,016         4,653,692

    Non-operating income (expenses):
    Interest income                                 10,589                --
    Interest expense                               (38,236)          (45,273)
    Total non-operating income (expense)           (27,647)          (45,273)

    Income before income taxes                   4,035,369         4,608,419
    Income tax (expense) benefit                  (357,722)         (417,878)
    Net income                                   3,677,647         4,190,541

    Other Comprehensive income - foreign
     currency translation adjustments               87,491         1,745,242
    Comprehensive income                        $3,765,138        $5,935,783

    Basic and Diluted
    Earnings per Share                               $0.09             $0.11
    Basic and Diluted
    Weighted-Average Shares Outstanding         42,278,938        37,278,938

                         CHINA PHARMA HOLDINGS, INC.

                                                 March 31,        December 31,
                                                    2009              2008
    Current Assets:
    Cash and cash equivalents                   $5,151,882        $6,927,149
    Trade accounts receivable, less
     allowance for doubtful
     accounts of $5,248,353 and
     $4,474,175, respectively                   41,046,443        36,008,095
    Other receivables, less allowance for
     doubtful accounts of $71,272 and
     $54,242, respectively                         210,717           163,957
    Advances to suppliers                        2,752,786         3,031,694
    Inventory                                   13,206,064        13,139,750
    Deferred tax assets                            585,159           461,596
    Total Current Assets                        62,953,051        59,732,241
    Non-current Assets:
    Property and equipment, net of
     accumulated depreciation of
     $1,596,729 and $1,483,267,
     respectively                                7,158,787         6,738,368
    Intangible assets, net of accumulated
     amortization of $716,537 and $547,567,
     respectively                                6,002,008         6,162,549
    Advances for purchases of intangible
     assets and property
     and equipment                               4,312,403         2,838,679
    Total Non-current Assets                    17,473,198        15,739,596
    TOTAL ASSETS                               $80,426,249       $75,471,837

    Current Liabilities:
    Trade accounts payable                      $2,225,006        $1,049,268
    Accrued expenses                                48,421            56,075
    Accrued taxes payable                        1,155,812         1,170,003
    Other payables                                  44,865            42,813
    Advances from customers                        723,345           693,178
    Other payables - related parties                75,741            75,741
    Short-term notes payable                     2,483,347         2,480,231
    Total Current Liabilities                    6,756,537         5,567,309
    Research and development commitments            36,520            36,474
    Total Liabilities                            6,793,057         5,603,783
    Stockholders' Equity:
    Common stock, $0.001 par value,
     60,000,000 shares authorized,
     42,278,938 and 42,278,938
     shares issued and
     outstanding, respectively                      42,279            42,279
    Additional paid-in capital                  21,066,338        21,066,338
    Retained earnings                           46,717,466        43,039,819
    Foreign currency translation
     adjustment                                  5,807,109         5,719,618
    Total Stockholders' Equity                  73,633,192        69,868,054
     EQUITY                                    $80,426,249       $75,471,837

SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: